Search
Now showing items 11-15 of 15
Warfarin-Rifampin-Gene (WARIF-G) Interaction: A Retrospective, Genetic, Case–Control Study
(
Wiley-Blackwell
, 2023 , Article)
Warfarin is extensively metabolized by cytochrome P450 2C9 (CYP2C9). Concomitant use with the potent CYP2C9 inducer, rifampin, requires close monitoring and dosage adjustments. Although, in theory, warfarin dose increase ...
Genetic polymorphism effect on warfarin–rifampin interaction: A case report and review of literature
(
Dove Medical Press
, 2021 , Article)
Warfarin–rifampin interaction has been reported since the 1970s. Due to rifampin’s strong induction of CYP2C9, most cases could not attain the target international normalized ratio (INR) despite warfarin dose escalation. ...
Genomewide association analysis of warfarin dose requirements in Middle Eastern and North African populations
(
Wiley-Blackwell
, 2022 , Article)
To date, there has been no genomewide association study (GWAS) from the Middle East and North African (MENA) region to identify genetic variants associated with warfarin dose variability using this approach. In this study, ...
Direct oral anticoagulants are effective and safe in the treatment of venous thromboembolism and atrial fibrillation in morbidly obese patients
(
Springer
, 2020 , Other)
There has always been unresolved uncertainty regarding the therapeutic utility of direct oral anticoagulants (DOACs) in morbidly obese patients (BMI > 40 kg/m2 or weight > 120 kg) with clinical indications for anticoagulant's ...
Potential Therapeutic Effects of Sodium Glucose-linked Cotransporter 2 Inhibitors in Stroke
(
Elsevier
, 2020 , Article Review)
Purpose: Stroke is the second leading cause of death and the third leading cause of disability worldwide. Diabetes mellitus and the associated hyperglycemia are important risk factors for acute ischemic stroke and are ...